
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is poised for success with the potential of TH103 to disrupt the market for wet AMD treatments. With strong results in preclinical and Phase 1 trials, the drug has shown promise in improving on current therapies for wet AMD. Along with a solid safety profile and patents for exclusivity, Kalaris has a strong chance of gaining a share of the highly lucrative wet AMD market. However, the company must navigate financial risks and competition from existing treatments.
Bears say
Kalaris Therapeutics is a company with potential but also faces significant challenges. While their TH103 drug shows promise, it competes in a highly competitive market with established players and safety concerns with similar drugs. Additionally, the company may struggle to expand its capabilities and may face difficulties in commercialization. These factors contribute to a negative outlook from a financial analyst's perspective.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares